Oruka Therapeutics, Inc. research snapshot
ORKA AI stock analysis reads Oruka Therapeutics as a high-conviction clinical-stage biotech whose lead asset, ORKA-001, delivered a 63.5% PASI 100 rate at Week 16 in the EVERLAST-A Phase 2a trial, a result in line with best-in-class IL-23 efficacy. At the August 3, 2026 data cutoff, ORKA closed at $94.80 with a market capitalization near $5.72 billion, after a roughly 600% one-year run that took the stock to a $99.00 high in late July. The ORKA AI stock forecast uses scenario ranges instead of a fixed price prediction because late-stage data, regulatory decisions, financing events, partnership outcomes and competitive moves can change the investment case quickly. This page is for information only and is not investment advice.
Current price
$94.80 close on August 3, 2026; 52-week range $12.84 to $99.00
Market cap
$5.72 billion market capitalization based on about 60.31 million shares
AI score
52 / 100
Rating
High-upside clinical-stage biotech with a validated Phase 2a efficacy signal for ORKA-001, pro forma cash above $1 billion, strong analyst support, but still pre-revenue with binary late-stage data, extreme volatility and high expectations priced in
Trend status
Strong uptrend, up about 600% over the past year and trading just below the $99.00 all-time high, well above the 50-day and 200-day moving averages, with high volatility and a 14.65% short position
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Oruka has no approved products or revenue. The engine is pipeline-driven: ORKA-001 (anti-IL-23 p19) reported a 63.5% PASI 100 rate at Week 16 in the EVERLAST-A Phase 2a trial, and ORKA-002 (anti-IL-17A/F) is advancing through Phase 2. Value depends entirely on whether late-stage trials confirm the early signal. | Low |
| Moat | No proven moat yet, but the profile is improving. If ORKA-001 confirms best-in-class efficacy with once or twice yearly dosing and a clean safety profile, it could carve a durable position against Skyrizi, Tremfya, Bimzelx and Cosentyx. Half-life-extended antibody engineering, the Halozyme Hypercon collaboration and intellectual property are potential moat sources that remain unproven until EVERLAST-B and Phase 3 replicate the Phase 2a data. | Low |
| Management | A seasoned team led by CEO Lawrence Klein and CMO Joana Goncalves with dermatology and immunology experience. Management executed a $700M offering priced at $72.50 in April 2026 and a Hypercon collaboration with Halozyme in May 2026. Key-person risk is elevated in the 68-employee organization, and recurring insider sales are a monitoring item. | Medium |
| Financial trend | No revenue and continuing GAAP losses: the Q1 2026 net loss was $31.8 million and TTM net income was about -$94 million. The April 2026 $700M offering lifted pro forma cash above $1 billion, which management expects to fund operations through a BLA filing for ORKA-001. Dilution is the tradeoff for the runway. | Medium |
| Valuation | At $94.80, ORKA trades at roughly 10x to 12x book value with no P/E or P/S because it has no revenue or profit. The $5.72B market cap versus over $1 billion pro forma cash implies the market assigns billions in value to the pipeline. The average analyst target is $148.17 with a range of $102 to $200. | Medium |
| Technical trend | Strong uptrend: the stock is up about 600% over the past year, closed at $94.80 on August 3, 2026, and sits just below the $99.00 all-time high set on July 31. Price is well above the 50-day moving average of $78.65 and the 200-day moving average of $49.35, with RSI near 60. | Medium |
| Risk level | Extreme. Risks include Phase 2b or Phase 3 failure, regulatory setbacks, competition from approved IL-23 and IL-17 inhibitors, dilution, insider selling, and binary clinical catalysts that can move the stock 20% to 50% in a session. Short interest is about 14.65% of shares outstanding. | High |
| AI confidence | Descriptive confidence is medium-high for current price, market cap, cash, share count and analyst data. Return confidence is very low because clinical-stage biotech outcomes depend on binary scientific and regulatory events that no AI model can predict reliably. | Low return confidence |
| Investment certainty | Very low. ORKA is a speculative biotech bet whose equity value tracks a small set of data readouts over the next 18 months. It is suitable only for investors who understand that a single negative data point can produce a large drawdown and who can tolerate a potential total loss. | Very low |
ORKA AI stock forecast
The ORKA AI stock forecast is scenario-based because Oruka has no revenue and its valuation depends on late-stage clinical outcomes. Using the $94.80 close on August 3, 2026 as a reference and analyst targets ranging from $102 to $200 (average $148.17), the mechanical outcomes over a 12 to 18 month framework are about $150 to $200 in a bullish case, $100 to $130 in a neutral case, and $40 to $70 in a bearish case.
$150 to $200
More likely if the 2H 2026 EVERLAST-A 28-week and 52-week data confirm durability and once-a-year dosing, EVERLAST-B replicates the Phase 2a efficacy, Phase 3 starts on schedule, and partnership or acquisition interest emerges. The reported ~$11 billion acquisition interest in sibling Paragon company Apogee shows that large pharma is paying attention to this asset class.
$100 to $130
More likely if long-term data are in line but not transformative, the stock consolidates near current levels while the market waits for EVERLAST-B and ORKA-002 readouts in 2027, and no new financing or deal catalyst emerges. Cash remains well above $1 billion in this scenario.
$40 to $70
More likely if EVERLAST-A durability data fade, safety signals appear, EVERLAST-B disappoints, Phase 3 is delayed, competition advances a better option, or dilutive financing is needed at a lower price. A move toward the 200-day moving average near $49 is possible in this scenario, with the roughly $17 per share net cash position acting as a longer-term floor.
ORKA AI technical analysis
ORKA AI technical analysis reflects an aggressive uptrend with very high volatility as of the August 3, 2026 data cutoff. Yahoo Finance and stockanalysis.com show a $94.80 close on August 3, a 52-week range of $12.84 to $99.00, a 50-day moving average of $78.65 and a 200-day moving average of $49.35. The stock is up about 600% over the past year and 214% year to date, with volume spikes on data and financing news.
| Level | Value | Why it matters |
|---|---|---|
| Current price reference | $94.80 close on August 3, 2026 | The stock pulled back from the $99.00 all-time high set on July 31, 2026, after a series of double-digit daily moves in June and July. |
| Immediate support | $88 to $92 | This zone covers the July 2026 consolidation and the $90.61 low on August 3. It is the first area to watch on a pullback. |
| Key support | $78.65 to $82 | The 50-day moving average of $78.65 and early July lows near $82 form the main support cluster. A hold above this area would preserve the uptrend. |
| Major support | $60 to $64 | This is the early June 2026 base before the breakout above $70. It marks the zone that would need to break to signal a broader trend change. |
| Near resistance | $97 to $99 | The $99.00 all-time high is the immediate resistance. A volume-confirmed break above it would signal trend continuation. |
| Upper resistance | $120 to $130 | H.C. Wainwright holds a $120 target and UBS raised its target to $130. These analyst levels represent the next upside zone if catalysts are positive. |
| Analyst target zone | $148 to $151 | The average analyst target is $148.17, with Stifel at $150 and BTIG at $151. This zone reflects the consensus upside if late-stage data stay positive. |
| Moving averages | 50-day $78.65; 200-day $49.35 | Price is well above both averages, which is typical of an extended uptrend but leaves limited nearby technical support. |
| Momentum | Strong but extended | The stock is up about 600% over one year and 214% year to date. RSI is near 60, so momentum is strong but no longer deeply overbought. |
| Volume | 20-day average near 958,000 shares | Volume spikes on news, such as 4.5 million shares on July 2 and 4.7 million on June 26. Watch for volume confirmation on any move above $99. |
| Short interest | 8.83 million shares, 14.65% of shares outstanding | Days to cover is about 5. A short squeeze can add upside volatility on positive data, but the high short base also adds downside risk on disappointment. |
| Invalidation | Close below $78.65, then below $70 | A sustained move below the 50-day moving average would suggest the uptrend is weakening. A break below the $60 to $64 zone would signal a potential trend reversal. |
ORKA AI trading strategy
The ORKA AI trading strategy below is a rules-based research framework, not personal advice. It connects price levels with clinical data timelines, cash runway, analyst targets, financing history and insider activity.
Map the position around the expected Q2 2026 earnings (around August 10 to 12, 2026), the 2H 2026 EVERLAST-A 28-week and 52-week data, and the 2027 EVERLAST-B and ORKA-002 readouts. Look for volume-confirmed moves near support rather than chasing news spikes, and compare price with analyst targets of $102 to $200.
Size the position for binary moves of 20% to 50%. A common risk management practice is to trim exposure before major data readouts and not add after a rapid run-up without a fresh catalyst. The short interest of 14.65% can amplify both directions.
If ORKA pulls back toward the $88 to $92 zone or the 50-day moving average near $78.65 without a negative catalyst, compare the lower price with pro forma cash above $1 billion, the pipeline timeline, analyst targets and insider selling patterns.
Do not buy every dip in a clinical-stage biotech. A pullback before data may reflect a fair reassessment rather than an opportunity. Check whether insider selling has accelerated before adding.
Track EVERLAST-A long-term data, EVERLAST-B enrollment and timing, ORCA-SURGE and ORCA-SPLASH progress, cash position and burn rate, analyst rating and target changes, Halozyme Hypercon milestones, insider transactions, and competitor data from Skyrizi, Bimzelx, Tremfya and Cosentyx.
Keep the position small relative to a diversified portfolio. Because a single negative readout can cut the value in half, no position in Oruka should be sized as if it were a stable compounding business.
Investment research summary
Patients and physicians would pay for Oruka monoclonal antibodies if they deliver high, durable rates of complete skin clearance with far less frequent dosing than today's approved IL-23 and IL-17 inhibitors. ORKA-001 hit a 63.5% PASI 100 rate at Week 16 in EVERLAST-A, and management is pursuing once or twice yearly dosing. The economic engine is pipeline-driven with no current product revenue.
The potential moat comes from half-life-extended antibody engineering, best-in-class efficacy, annual dosing convenience, the Halozyme Hypercon collaboration and intellectual property. It is unproven until EVERLAST-B and Phase 3 replicate the Phase 2a signal. The approved psoriasis market is crowded with Skyrizi, Tremfya, Bimzelx and Cosentyx.
The thesis fails if EVERLAST-A durability data fade, EVERLAST-B does not replicate the efficacy, safety signals appear, Phase 3 is delayed, competition advances a better or cheaper option, or the company needs dilutive financing at a low price. A 14.65% short position and recurring insider sales are factors to watch.
The leadership team brings relevant biopharma experience in dermatology and immunology and has executed well on financing and partnering: a $700M offering at $72.50 in April 2026 and a Hypercon collaboration with Halozyme in May 2026. The small team of 68 employees raises key-person risk, and insider sales are a monitoring item.
Psoriasis and inflammatory disease are large, growing markets with validated IL-23 and IL-17 mechanisms. The push toward complete clearance and infrequent dosing is an active commercial trend. Sibling Paragon company Apogee drew reported ~$11 billion acquisition interest, showing that large pharma is willing to pay for these assets.
The $5.72B market cap and over $1 billion pro forma cash imply the market assigns billions in value to a pipeline that is still pre-Phase 3. Margin of safety is low until late-stage data de-risk the story. The average analyst target of $148.17 represents upside only if the data remain positive.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $94.80 close on August 3, 2026 | stockanalysis.com and Yahoo Finance | August 3, 2026 |
| Market capitalization | $5.72 billion based on about 60.31 million shares | stockanalysis.com | August 3, 2026 |
| 52-week range | $12.84 to $99.00 | stockanalysis.com and Yahoo Finance | August 3, 2026 |
| Cash position | $496.0 million in cash, cash equivalents and marketable securities as of March 31, 2026; pro forma above $1 billion after the April 2026 $700M offering | Oruka Q1 2026 press release and Jefferies conference transcript | August 3, 2026 |
| Q1 2026 net loss | -$31.8 million (R&D $29.1 million; G&A $7.3 million) | Oruka Q1 2026 press release | August 3, 2026 |
| TTM net income | about -$94 million; TTM EPS about -$1.93 | Yahoo Finance key statistics | August 3, 2026 |
| Price/book ratio | about 10.0 (stockanalysis.com) to 12.0 (Yahoo Finance, mrq) | stockanalysis.com and Yahoo Finance | August 3, 2026 |
| Analyst consensus and targets | Strong Buy from 13 analysts; average target $148.17 with a range of $102 to $200 | stockanalysis.com forecast (S&P Global) | August 3, 2026 |
| Moving averages and momentum | 50-day MA $78.65; 200-day MA $49.35; RSI near 60 | stockanalysis.com statistics | August 3, 2026 |
| Short interest | 8.83 million shares; 14.65% of shares outstanding; about 5 days to cover | stockanalysis.com statistics | August 3, 2026 |
This ORKA AI stock analysis is an informational research tool only. It is not investment advice, a solicitation, or a personalized recommendation. Forecast scenarios are based on available public data as of the stated cutoff date and can be wrong if clinical trial results, regulatory decisions, competitive dynamics, financing needs, analyst estimates or market conditions change. Clinical-stage biotech investments carry a risk of total capital loss.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
